EMA to review Basilea's isavuconazole

EMA accepted for review an MAA from Basilea Pharmaceutica AG (SIX:BSLN) for isavuconazole ( BAL8557) to treat invasive aspergillosis and mucormycosis (zygomycosis). Last month, partner Astellas Pharma...